Autres langues Kura Oncology, Inc.

Actions

KURA

US50127T1097

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
19,65 ^USD	+3,42%		+12,09%	+36,65%

22/04	Kura Oncology, Inc. reçoit la désignation de Breakthrough Therapy pour le ziftomenib dans la LMA mutante NPM1	CI
14/03	Transcript : Kura Oncology, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 09:00 AM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Kura Oncology to Report First Quarter 2024 Financial Results	25/04
Sector Update: Health Care Stocks Advance Premarket Monday	22/04
Kura Oncology Gets Breakthrough Designation For Leukemia Therapy	22/04
Kura Oncology Says Potential Leukemia Drug Ziftomenib Gets FDA Breakthrough Therapy Designation; Shares Rise Pre-Bell	22/04
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML	22/04
Kura Oncology, Inc. Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML	22/04
Kura Oncology to Participate in Stifel Targeted Oncology Forum	10/04
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05/04
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma	06/03
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma	06/03
KURA ONCOLOGY REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)	04/03
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/03
Kura Oncology: Q4 Earnings Snapshot	27/02
Kura Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Kura Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/02
Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results	27/02
Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia	26/02
Kura Oncology, Inc. Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia	26/02
Kura Oncology to Participate in Three Upcoming Investor Conferences	22/02
Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results	20/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Kura Oncology, Inc.

Actions

KURA

US50127T1097

Autres langues

Filtres